Clinical Trial Update: Nab-paclitaxel Plus Camrelizumab and S-1 Conversion Therapy for Gastric Cancer With Positive Exfoliative Cancer Cells [Phase 2]

View source ↗

Summary

Phase 2 study evaluating nab-paclitaxel plus camrelizumab and S-1 conversion therapy for gastric cancer with positive exfoliative cancer cells (exfoliative cell…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer

Drugs mentioned

• Camrelizumab (camrelizumab)
• Nab-paclitaxel (paclitaxel protein-bound)
• S-1 (tegafur/gimeracil/oteracil)

Snippet

Sponsor: Hebei Medical University | Conditions: Gastric Cancer | Phase 2 | Status: UNKNOWN